<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521699</url>
  </required_header>
  <id_info>
    <org_study_id>20-005047</org_study_id>
    <nct_id>NCT04521699</nct_id>
  </id_info>
  <brief_title>Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.</brief_title>
  <acronym>CalmiGo</acronym>
  <official_title>Examination of the Impact of CalmiGo's Stress Management Device on Vascular Health and Cardiovascular Disease Risk , and Markers of Mental Stress in Patients Following a Myocardial Infarction Participating in Clinically Indicated Cardiac Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CalmiGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if there are significant differences with&#xD;
      respect to baseline between those randomized to CGo and standard-of-care versus&#xD;
      standard-of-care alone after completing 12-weeks of therapy in terms of peripheral&#xD;
      endothelial function measured by EndoPAT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients who have recently had an acute Myocardial Infarction ( heart attack) and are&#xD;
      under going clinically indicated cardiac rehabilitation will undergo baseline testing&#xD;
      including EndoPAT testing, mental stress testing, blood tests for cardiovascular disease&#xD;
      biomarkers , physical assessments &amp; survey questionnaires. Patients then will be randomized&#xD;
      to either CalmioGO stress management device + standard of care treatment or just standard of&#xD;
      care treatment. Those randomized to CalmiGO stress management device treatment will be&#xD;
      instructed to use the hand device much like an inhaler once a day for 12 weeks. After 12&#xD;
      weeks of rehabilitation both groups will return for reassessment of baseline tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral endothelial function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurements made at baseline will be significantly different between those randomized to CalmioGo + standard of care to those receiving only standard of care treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical assessments, cardiovascular disease biomarker blood tests as well resilience, joy, gratitude, mindfulness, health behavior , overall quality of life &amp; perceived stress.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurements made at baseline will be significantly different between those randomized to CalmiGo + standard of care then those to just standard of care.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>CalmioGo + Standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Stand of care alone with 12 weeks of Cardiac rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CalmioGO Stress management device</intervention_name>
    <description>CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.</description>
    <arm_group_label>CalmioGo + Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Ability to use the CamliGo device for 12-weeks&#xD;
&#xD;
          -  Willingness to complete study questionnaires, blood tests,&amp; EndoPat testing at the&#xD;
             beginning and end of study&#xD;
&#xD;
          -  Patients who have had a recent MI who will be undergoing clinically indicated Cardiac&#xD;
             Rehabilitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant Patient&#xD;
&#xD;
          -  Cognitively impaired patients&#xD;
&#xD;
          -  Patient with Bipolar disorder, psychosis or delusional disorder&#xD;
&#xD;
          -  History of substance abuse or dependence&#xD;
&#xD;
          -  History of suicidality&#xD;
&#xD;
          -  Unstable cardiovascular or pulmonary disease&#xD;
&#xD;
          -  History of seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Lerman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven A Zincke</last_name>
    <phone>507-255-0607</phone>
    <email>zincke.steven@Mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven A Zincke</last_name>
      <phone>507-255-0607</phone>
      <email>zincke.steven@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Amir Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amir Lerman</investigator_full_name>
    <investigator_title>Dr. Amir Lerman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

